Breast cancer: Current and future endocrine therapies

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Molecular and Cellular Endocrinology

• Publication date

  2014-01-25

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.mce.2013.08.001PMID 23933149
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2019cited by this paper
• Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial

  2016cited by this paper
• A phase II trial of low-dose estradiol in postmenopausal women with advanced breast cancer and acquired resistance to aromatase inhibition.

  2015cited by this paper
• Edinburgh Research Explorer Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 random

  2013cited by this paper
• Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial.

  2013cited by this paper
• Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor.

  2013cited by this paper
• Oestrogen increases the activity of oestrogen receptor negative breast cancer stem cells through paracrine EGFR and Notch signalling

  2013cited by this paper
• Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer

  2013cited by this paper
• aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer.

  2013cited by this paper
• Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer.

  2013cited by this paper
• Abstract 1072: MM-121/SAR256212, an anti-ErbB3 antibody, restores sensitivity to letrozole and delays the onset of resistance in an ER+ breast cancer model.

  2013cited by this paper
• Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial.

  2013cited by this paper
• HDAC Inhibitor Entinostat Restores Responsiveness of Letrozole-Resistant MCF-7Ca Xenografts to Aromatase Inhibitors through Modulation of Her-2

  2013cited by this paper
• Progesterone signalling in breast cancer: a neglected hormone coming into the limelight

  2013cited by this paper
• Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial.

  2013cited by this paper
• A phase I dose escalation study to determine the optimal biological dose of irosustat, an oral steroid sulfatase inhibitor, in postmenopausal women with estrogen receptor-positive breast cancer

  2013cited by this paper
• Emerging targeted agents in metastatic breast cancer

  2013cited by this paper
• Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer.

  2013cited by this paper
• 55O_PRPROGNOSTIC AND PREDICTIVE VALUE OF IHC4 AND ERB1 IN THE INTERGROUP EXEMESTANE STUDY (IES) - ON BEHALF OF THE PATHIES INVESTIGATORS

  2013cited by this paper
• Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

  2013cited by this paper
• Phase II randomized study of the EGFR, HER2, HER3 signaling inhibitor AZD8931 in combination with anastrozole (A) in women with endocrine therapy (ET) naive advanced breast cancer (MINT).

  2013cited by this paper
• Ulipristal acetate versus placebo for fibroid treatment before surgery.

  2012cited by this paper
• Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial.

  2012cited by this paper
• FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer.

  2012cited by this paper
• The immninent dawn of SPRMs in obstetrics and gynecology.

  2012cited by this paper
• Mechanisms of estrogen-independent breast cancer growth driven by low estrogen concentrations are unique versus complete estrogen deprivation

  2012cited by this paper
• Abstract S1-7: Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer – First efficacy results from the LEA study.

  2012cited by this paper
• Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study.

  2012cited by this paper
• Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial.

  2012cited by this paper
• Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study.

  2012cited by this paper
• Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment.

  2012cited by this paper
• Abstract P2-14-04: A Phase Ib Dose Escalation Trial of RO4929097 (a γ-secretase inhibitor) in Combination with Exemestane in Patients with ER + Metastatic Breast Cancer.

  2012cited by this paper
• AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family.

  2012cited by this paper
• Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

  2012cited by this paper
• A Phase II Trial of Low Dose Estradiol in Postmenopausal Women with Advanced Breast Cancer and Acquired Resistance to an Aromatase Inhibitor.

  2012cited by this paper
• Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study.

  2012cited by this paper
• Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor–positive metastatic breast cancer

  2012cited by this paper
• Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study

  2012cited by this paper
• Oestrogen and breast cancer: results from the WHI trial.

  2012cited by this paper
• The insulin and insulin-like growth factor receptor family in neoplasia: an update

  2012cited by this paper
• Abstract S1-6: Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (BC)

  2012cited by this paper
• Targeting the androgen receptor (AR) in women with AR+ ER-/PR- metastatic breast cancer (MBC).

  2012cited by this paper
• Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial.

  2012cited by this paper
• AIB1:ERα Transcriptional Activity Is Selectively Enhanced in Aromatase Inhibitor–Resistant Breast Cancer Cells

  2012cited by this paper
• Combination anastrozole and fulvestrant in metastatic breast cancer.

  2012cited by this paper
• Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2011cited by this paper
• Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: a phase II Trial of the Sarah Cannon Oncology Research Consortium.

  2011cited by this paper
• PD01-01: Randomized Phase II Trial of Fulvestrant with or without Dasatinib in Postmenopausal Patients with Hormone Receptor-Positive Metastatic Breast Cancer Previously Treated with an Aromatase Inhibitor.

  2011cited by this paper
• Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial.

  2011cited by this paper
• Functional activation of the estrogen receptor-α and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole.

  2011cited by this paper
• PD01-02: Randomized Phase II Study of Dasatinib vs Placebo in Addition to Exemestane in Advanced ER/PR-Positive Breast Cancer [BMS CA180-261 Study].

  2011cited by this paper
• Phase I study of abiraterone acetate (AA) in patients (pts) with estrogen receptor- (ER) or androgen receptor (AR) -positive advanced breast carcinoma resistant to standard endocrine therapies.

  2011cited by this paper
• A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors

  2011cited by this paper
• Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

  2011cited by this paper
• Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes

  2011cited by this paper
• Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment.

  2011cited by this paper
• Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time

  2011cited by this paper
• A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer

  2011cited by this paper
• Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor–Positive Metastatic Breast Cancer: A Randomized Phase II Study

  2011cited by this paper
• Abiraterone and increased survival in metastatic prostate cancer.

  2011cited by this paper
• Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study.

  2011cited by this paper
• Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031.

  2011cited by this paper
• Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies.

  2011cited by this paper
• A phase II study of ridaforolimus (RIDA) and dalotuzumab (DALO) in estrogen receptor-positive (ER+) breast cancer.

  2011cited by this paper
• Phase II trial of the dual IGF-1R/IR inhibitor BMS-754807 with or without letrozole in aromatase inhibitor-resistant breast cancer.

  2011cited by this paper
• Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer.

  2011cited by this paper
• Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole – of clinical importance?

  2011cited by this paper
• Reversal of Tamoxifen Resistance (Hormone Resistance) by Addition of Sirolimus (mTOR Inhibitor) in Metastatic Breast Cancer

  2011cited by this paper
• Bosutinib and exemestane (EXE) versus EXE alone in postmenopausal (postm) women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (ABC).

  2011cited by this paper
• Significance of ER–Src axis in hormonal therapy resistance

  2011cited by this paper
• Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth.

  2011cited by this paper
• ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer.

  2011cited by this paper
• Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.

  2011cited by this paper
• Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma.

  2011cited by this paper
• Isolated and combined action of tamoxifen and metformin in wild-type, tamoxifen-resistant, and estrogen-deprived MCF-7 cells

  2011cited by this paper
• P1-17-01: Figitumumab Plus Exemestane Versus Exemestane as First-Line Treatment of Postmenopausal Hormone Receptor-Positive Advanced Breast Cancer: A Randomized, Open-Label Phase II Trial.

  2011cited by this paper
• Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial

  2011cited by this paper
• Phase II, Randomized Trial to Compare Anastrozole Combined with Gefitinib or Placebo in Postmenopausal Women with Hormone Receptor–Positive Metastatic Breast Cancer

  2010cited by this paper
• Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women.

  2010cited by this paper
• On Cancer of the Breast

  2010cited by this paper
• Co-targeting the insulin-like growth factor I receptor enhances growth-inhibitory and pro-apoptotic effects of anti-estrogens in human breast cancer cell lines

  2010cited by this paper
• Increased estrogen sulfatase (STS) and 17β-hydroxysteroid dehydrogenase type 1(17β-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients

  2010cited by this paper
• Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.

  2010cited by this paper
• An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation.

  2010cited by this paper
• Surgical oncology: Why biopsying metastatic breast cancer should be routine

  2010cited by this paper
• In vitro characterization of ZK 230211--A type III progesterone receptor antagonist with enhanced antiproliferative properties.

  2010cited by this paper
• Abstract PD05-12: Combination of Notch Inhibitor MK-0752 and Endocrine Therapy for Early Stage ERα + Breast Cancer in a Presurgical Window Pilot Study

  2010cited by this paper
• FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer.

  2010cited by this paper
• American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.

  2010cited by this paper
• Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen.

  2010cited by this paper
• Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.

  2010cited by this paper
• Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.

  2010cited by this paper
• Suppression of ovarian function in combination with an aromatase inhibitor as treatment for advanced breast cancer in pre-menopausal women.

  2010cited by this paper
• Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer.

  2010cited by this paper
• Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy.

  2010cited by this paper
• Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer.

  2010cited by this paper
• Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.

  2009cited by this paper
• Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.

  2009cited by this paper
• Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development.

  2009cited by this paper
• PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

  2009cited by this paper

• Assessing endocrine resistance: monitoring circulating ESR1 mutations in Irosustat-treated ER positive breast cancer

  2025cites this paper
• Synthesis, Anti-proliferation, Apoptosis Induction in Breast Cancer Cells, and Aromatase Inhibition of Coumarin-Triazole Hybrids: In Vitro and In Silico Studies.

  2025cites this paper
• Chitosan and hyaluronic acid in breast cancer treatment: Anticancer efficacy and nanoparticle and hydrogel development.

  2025cites this paper
• Evaluating clinical response to primary endocrine therapy in elderly breast cancer patients in routine practice

  2025cites this paper
• Functionalized nitrogen- and chalcogen-containing heterocyclic compounds as aromatase inhibitors: Design, synthesis and biological evaluation.

  2025cites this paper
• ESMO-ESTRO framework for assessing the interactions and safety of combining radiotherapy with targeted cancer therapies or immunotherapy.

  2025cites this paper
• 2-methoxyestradiol sensitizes tamoxifen-resistant MCF-7 breast cancer cells via downregulating HIF-1α

  2024cites this paper
• Progesterone and progesterone receptors in breast cancer: past, present, and future

  2024cites this paper
• Radiological and Molecular Analysis of Radioiodinated Anastrozole and Epirubicin as Innovative Radiopharmaceuticals Targeting Methylenetetrahydrofolate Dehydrogenase 2 in Solid Tumors

  2024cites this paper
• Tetrahydroisoquinolines – an updated patent review for cancer treatment (2016 – present)

  2024cites this paper
• Delineating intra-tumoral heterogeneity and tumor evolution in breast cancer using precision-based approaches

  2023cites this paper
• Anticancer or carcinogenic? The role of estrogen receptor β in breast cancer progression.

  2023cites this paper
• Benzoxazole-appended piperidine derivatives as novel anticancer candidates against breast cancer.

  2023cites this paper
• Breast Tumor Cells Evade the Cytotoxic Action of Anastrozole, Aspirin, and Clopidogrel Cocktail.

  2023cites this paper
• FDXR drives primary and endocrine-resistant tumor cell growth in ER+ breast cancer via CPT1A-mediated fatty acid oxidation

  2023cites this paper
• Resistance to hormone therapy in breast cancer cells promotes autophagy and EGFR signaling pathway

  2023cites this paper
• Synthesis, Characterization, Hirshfeld Surface Analysis, DFT Study and Molecular Docking of 1,3‐Bis(4‐chlorophenyl)‐ 5‐(4‐chlorobenzyl)‐1,3,5‐triazinane

  2023cites this paper
• Design, synthesis, molecular docking and molecular dynamics studies of novel triazolothiadiazine derivatives containing furan or thiophene rings as anticancer agents.

  2022cites this paper
• SAKK 21/12: a phase II trial of transdermal CR1447 in breast cancer patients

  2022cites this paper
• A review on diverse heterocyclic compounds as the privileged scaffolds in non-steroidal aromatase inhibitors.

  2021cites this paper
• Mechanisms of Drug Resistance and Use of Nanoparticle Delivery to Overcome Resistance in Breast Cancers.

  2021cites this paper
• Synergistic Cytotoxicity between Elephantopus scaber and Tamoxifen on MCF-7-Derived Multicellular Tumor Spheroid

  2021cites this paper
• The prognostic value of cyclin D1 in breast cancer patients treated with hormonal therapy: A pilot study.

  2021cites this paper
• Breast cancer animal models and applications

  2020cites this paper
• Progesterone and Progesterone Receptors in Breast Cancer: Past, Present, Future.

  2020cites this paper
• The Dysregulated Pharmacology of Clinically Relevant ESR1 Mutants is Normalized by Ligand-activated WT Receptor

  2020cites this paper
• Syntheses and Biological Activities of triazole-based Sulfonamides

  2020cites this paper
• Targeting STAT3 signaling using stabilised sulforaphane (SFX-01) inhibits endocrine resistant stem-like cells in ER-positive breast cancer

  2020cites this paper
• Notch Signaling in Breast Cancer: A Role in Drug Resistance

  2020cites this paper
• Targeting STAT3 signalling using stabilised sulforaphane (SFX-01) inhibits endocrine resistant stem-like cells in ER-positive breast cancer

  2020cites this paper
• HNRNPA2/B1 is upregulated in endocrine-resistant LCC9 breast cancer cells and alters the miRNA transcriptome when overexpressed in MCF-7 cells

  2019cites this paper
• Efficacy and acceptability of neoadjuvant endocrine therapy in patients with hormone receptor‐positive breast cancer: A network meta‐analysis

  2019cites this paper
• Overexpression of the steroidogenic acute regulatory protein in breast cancer: Regulation by histone deacetylase inhibition.

  2019cites this paper
• Structure Guided Molecular Docking Assisted Alignment Dependent 3DQSAR Study on Steroidal Aromatase Inhibitors (SAIs) as Anti-breast Cancer Agents

  2019cites this paper
• Breast cancer follow-up after a primary diagnosis: A confused picture.

  2019cites this paper
• Synthesis, molecular docking, and QSAR study of bis-sulfonamide derivatives as potential aromatase inhibitors.

  2019cites this paper
• Novel triazole-tetrahydroisoquinoline hybrids as human aromatase inhibitors.

  2019cites this paper
• The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer

  2019cites this paper
• Overcoming endocrine resistance in hormone receptor-positive breast cancer.

  2018cites this paper
• Metastatic and triple-negative breast cancer: challenges and treatment options

  2018cites this paper
• Transcription regulation of MYB: a potential and novel therapeutic target in cancer.

  2018cites this paper
• Mouse models of breast cancer in preclinical research

  2018cites this paper
• Synthesis and molecular docking of N,N'-disubstituted thiourea derivatives as novel aromatase inhibitors.

  2018cites this paper
• 18F-Fluoroestradiol Tumor Uptake Is Heterogeneous and Influenced by Site of Metastasis in Breast Cancer Patients

  2018cites this paper
• How to overcome endocrine resistance in early and metastatic breast cancer

  2018cites this paper
• Impairment of the Gnα11-controlled expression of claudin-1 and MMP-9 and collective migration of human breast cancer MCF-7 cells by DHEAS.

  2018cites this paper
• Synthesis, molecular docking, and QSAR study of sulfonamide-based indoles as aromatase inhibitors.

  2018cites this paper
• 18 F-Fluoroestradiol Tumor Uptake Is Heterogeneous and Influenced by Site of Metastasis in Breast Cancer Patients

  2018cites this paper
• Good Guy or Bad Guy? The Duality of Wild-Type p53 in Hormone-Dependent Breast Cancer Origin, Treatment, and Recurrence

  2018cites this paper
• Exploring the impact of anti-oestrogen resistance on the capacity of breast cancer cells to modulate bone cell function and their sensitivity to bisphosphonates

  2017cites this paper
• Prognostic Impact of Progesterone Receptor Status in Chinese Estrogen Receptor Positive Invasive Breast Cancer Patients

  2017cites this paper
• In vivo models in breast cancer research: progress, challenges and future directions

  2017cites this paper
• The effects of breast cancer therapy on estrogen receptor signaling throughout the body

  2017cites this paper
• Fundamental Pathways in Breast Cancer 3: Estrogen Biology

  2017cites this paper
• Clinical investigation of RAD1901, a novel estrogen receptor ligand, for the treatment of postmenopausal vasomotor symptoms: a phase 2 randomized, placebo-controlled, double-blind, dose-ranging, proof-of-concept trial

  2017cites this paper
• Investigating barriers to tamoxifen adherence in women with breast cancer

  2017influential citation
• IPET study: an FLT-PET window study to assess the activity of the steroid sulfatase inhibitor irosustat in early breast cancer

  2017cites this paper
• IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients

  2017cites this paper
• Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis

  2017cites this paper
• Identification of miRNAs as biomarkers for acquired endocrine resistance in breast cancer.

  2017cites this paper
• Dysregulation of Aromatase in Breast, Endometrial, and Ovarian Cancers: An Overview of Therapeutic Strategies.

  2016cites this paper
• Network Meta-Analysis of the Effectiveness of Neoadjuvant Endocrine Therapy for Postmenopausal, HR–Positive Breast Cancer

  2016cites this paper
• Suppression of long non-coding RNA CCAT2 improves tamoxifen-resistant breast cancer cells’ response to tamoxifen

  2016cites this paper
• Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer

  2016cites this paper
• KSP inhibitor SB743921 inhibits growth and induces apoptosis of breast cancer cells by regulating p53, Bcl-2, and DTL

  2016cites this paper
• Estrogen-regulated extracellular matrix remodeling genes in MCF-7 breast cancer cells

  2016cites this paper
• The long range regulation of breast cancer associated genes

  2016cites this paper
• NANOTECHNOLOGY APPROACH FOR TARGETED TREATMENT OF TRIPLE NEGATIVE BREAST CANCER

  2016cites this paper
• Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant

  2016cites this paper
• The silencing of HER2/neu gene expression in a breast cancer cell model using cationic lipid based delivery systems.

  2016cites this paper
• Endocrine treatment-associated cognitive impairment in breast cancer survivors: evidence from published studies

  2016cites this paper
• Anacardic Acid, Salicylic Acid, and Oleic Acid Differentially Alter Cellular Bioenergetic Function in Breast Cancer Cells

  2016cites this paper
• Effets membranaires du récepteur alpha des œstrogènes - Une question de spécificité tissulaire

  2015cites this paper
• Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion

  2015cites this paper
• Activation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression

  2015cites this paper
• Anti-estrogen Resistance in Human Breast Tumors Is Driven by JAG1-NOTCH4-Dependent Cancer Stem Cell Activity

  2015cites this paper
• Revealing the Complexity of Breast Cancer by Next Generation Sequencing

  2015cites this paper
• [Tissue-specific membrane effects of estrogen receptor alpha].

  2015cites this paper
• Tamoxifen induces a pluripotency signature in breast cancer cells and human tumors

  2015cites this paper
• Efficacy and Safety of Pomegranate Medicinal Products for Cancer

  2015cites this paper
• Revisiting the estrogen receptor pathway and its role in endocrine therapy for postmenopausal women with estrogen receptor-positive metastatic breast cancer

  2015cites this paper
• Efficacy and tolerance of everolimus in 123 consecutive advanced ER positive, HER2 negative breast cancer patients. A two center retrospective study.

  2015cites this paper
• Synthesis and molecular docking of 1,2,3-triazole-based sulfonamides as aromatase inhibitors.

  2015cites this paper
• Roles for miRNAs in endocrine resistance in breast cancer.

  2015cites this paper
• Personalized Therapies for Cancer Treatment

  2015cites this paper
• Chromatin and Epigenetic Determinants of Resistance to Aromatase Inhibitors

  2015cites this paper
• Chapter 14 – Hormones of Pregnancy, Parturition and Lactation

  2015cites this paper
• Approches thérapeutiques des cancers du sein hormonodépendants et conseils à l'officine

  2015cites this paper
• CCNA2 Is a Prognostic Biomarker for ER+ Breast Cancer and Tamoxifen Resistance

  2014cites this paper
• The effectiveness of an intervention by specialist breast care nurses to address the perceived needs and enhance the quality of life of women with breast cancer receiving follow-up care: A randomised controlled trial.

  2014cites this paper
• 7 α-allylandrostanes as new aromatase inhibitors: biological effects in hormone-dependent and hormone-resistant breast cancer cells

  2014cites this paper
• Effect of adjuvant endocrine therapy on hormonal levels in premenopausal women with breast cancer: the ProBONE II study

  2014cites this paper
• Malignant stroma increases luminal breast cancer cell proliferation and angiogenesis through platelet-derived growth factor signaling

  2014cites this paper
• The Emerging Role of QSOX1 in Cancer

  2014cites this paper
• CCNB1 is a prognostic biomarker for ER+ breast cancer.

  2014cites this paper
• A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells

  2014cites this paper
• NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer

  2014cites this paper
• Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancer

  2014cites this paper
• Seven In Absentia Homolog 2 (SIAH2) downregulation is associated with tamoxifen resistance in MCF-7 breast cancer cells.

  2014cites this paper
• Regulation of apoptosis by long non-coding RNA GAS5 in breast cancer cells: implications for chemotherapy

  2014cites this paper